-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Fusion Pharmaceuticals Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2022 to Q1 2024.
- Fusion Pharmaceuticals Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$405K, a 18% increase year-over-year.
- Fusion Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $845K.
- Fusion Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$3.16M, a 219% decline from 2021.
- Fusion Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$991K, a 72% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)